Novo Nordisk strike by U.S. check to new insulin drug

<p>COPENHAGEN (Reuters) – Danish drugmaker <span>Novo Nordisk</span>, a world’s biggest <span>insulin</span> maker, pronounced on Friday that U.S. <span>health regulators</span> had extended their examination of a new ultra-long-acting insulin Tresiba, or degludec, to cruise serve data.</p>
<p> The astonishing check is a beating given degludec is a pivotal new product with that Novo hopes to connect a position in a fast-growing diabetes market.</p>
<p> Shares in a organisation fell 3.1 percent by 0740 GMT.</p>
<p> A preference on a medicines is now approaching on Oct 29, when a outcome will also be delivered on a associated multiple prolongation called Ryzodeg, or degludecplus. Both drugs are designed to provide form 1 and form 2 diabetes.</p>
<p> The <span>U.S. Food and Drug Administration</span> asked for serve information construct...